March 2013

 

In this Supplement

The New Era of Drug Elution Has Arrived

Experts share how the drug effect of Zilver PTX is changing SFA treatment.

Issue

Supplement

Download a PDF of this supplement

Treating Femoropopliteal Occlusive Disease

What will be the workhorse therapy to address this disease over the next 3 to 5 years?

By Gary M. Ansel, MD; William A. Gray, MD; and Dierk Scheinert, MD

Why Drug-Eluting Stents Are Cost Effective in the Superficial Femoral Artery

The importance of cost effectiveness in health care is accelerating. Implanting drug-eluting stents in the superficial femoral artery may offer a safe, effective, and economically valuable solution.

By Mark W. Burket, MD

The Challenges of Bringing Drug Elution to the US Market

Cook Medical Vice President Rob Lyles provides insight on the approval and launch process of Zilver PTX in the United States, as well as next steps in the evolution of drug-eluting therapies.

Why Drug-Eluting Stents Are My Gold Standard

Experience with patients treated with Zilver PTX.

By Hiroyoshi Yokoi, MD, and Fabrizio Fanelli, MD
 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.